Pharma IPR 2018

The recently concluded 2018 Pharma IPR Conference saw Ranjna Mehta-Dutt (Partner) from the Firm participate in a panel discussion on ‘Patents vs. Early Market Entry of Indian Generics’ that addressed questions on whether India Inc. was investing right and the co-existence of innovators and generics in the current patent scenario.

During the discussion, Ms. Dutt shared her views on the existence of a fine balance in the nature of opportunities available to both innovators and generic drug manufacturers in India and how each could safeguard their interests. She also offered her perspective on relative positions in India, the US and Europe. The Pharma IPR Conference is a widely attended annual event that facilitates  interaction between Indian pharmaceutical companies and IP attorneys practicing in different jurisdictions across the globe. This year’s conference took place in Mumbai on March 7-9, 2018 and was also attended by Neha Srivastava (Managing Associate).



As per the rules of the Bar Council of India, we are not permitted to solicit work or advertise in any manner. By proceeding further and clicking on “I Agree” below, the user acknowledges that the transmission, receipt or use of the information on our website does not tantamount to solicitation, advertisement, inducement or personal communication of any sort for and on behalf of the Firm so as to create an attorney-client relationship.

The information provided herein should not be interpreted as legal advice, for which the user must make independent inquiries. Whilst every effort has been taken to ensure the accuracy of the contents of this website, Remfry & Sagar disclaims all liability arising from reliance placed by the user or any other third party on the information contained therein.